AACR 2023 | Phase I/II trial of elraglusib in solid tumors

Taylor Weiskittel, Mayo Clinic, Rochester, MN, discusses findings from a Phase I/II trial (NCT03678883) of elraglusib, a GSK-3 inhibitor in heavily pre-treated patients with solid malignancies. The drug was well tolerated with durable responses reported overall. Additional analysis of TCR sequencing and cytokine profiles will elucidate biomarkers of response to identify patients who will benefit more from GSK-3. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.